ATE92107T1 - N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. - Google Patents

N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Info

Publication number
ATE92107T1
ATE92107T1 AT90304575T AT90304575T ATE92107T1 AT E92107 T1 ATE92107 T1 AT E92107T1 AT 90304575 T AT90304575 T AT 90304575T AT 90304575 T AT90304575 T AT 90304575T AT E92107 T1 ATE92107 T1 AT E92107T1
Authority
AT
Austria
Prior art keywords
fusion proteins
serum albumin
human serum
terminal fragments
containing fusion
Prior art date
Application number
AT90304575T
Other languages
English (en)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE92107T1 publication Critical patent/ATE92107T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90304575T 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. ATE92107T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides
EP90304575A EP0399666B1 (de) 1989-04-29 1990-04-26 N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen

Publications (1)

Publication Number Publication Date
ATE92107T1 true ATE92107T1 (de) 1993-08-15

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90304575T ATE92107T1 (de) 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Country Status (7)

Country Link
EP (2) EP0407008A3 (de)
AT (1) ATE92107T1 (de)
DE (1) DE69002395T2 (de)
DK (1) DK0399666T3 (de)
ES (1) ES2060033T3 (de)
GB (1) GB8909919D0 (de)
WO (1) WO1990013306A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69012950T2 (de) * 1989-10-13 1995-03-16 Takara Shuzo Co Antikrebsmittel.
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001286688A1 (en) * 2000-08-25 2002-03-13 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
EP2076533B1 (de) 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
EA200901494A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
PL2318029T3 (pl) 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
EP2398827A2 (de) 2009-02-19 2011-12-28 Glaxo Group Limited Verbesserte anti-tnfr1-polypeptide, variable antikörperdomänen und antagonisten
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
PE20121564A1 (es) 2009-10-27 2012-11-29 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EA201291180A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR20140039257A (ko) 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
SG11201401717VA (en) 2011-11-04 2014-05-29 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
CN105793411B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
PL3298140T3 (pl) 2015-05-19 2024-11-12 Yale University Kompozycje do leczenia patologicznych stanów zwapnienia i sposoby ich stosowania
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
WO2020152367A1 (en) 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
US20230220048A1 (en) 2019-09-06 2023-07-13 Novartis Ag Therapeutic fusion proteins
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
EP4514846A1 (de) 2022-04-26 2025-03-05 Novartis AG Gegen il-13 und il-18 gerichtete multispezifische antikörper
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4389762A1 (de) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitoren der dux4-aktivität und ihre therapeutische verwendung.
CN116574173A (zh) * 2023-06-25 2023-08-11 浙江诸暨聚源生物技术有限公司 蛋白稳定性增强的重组人源纤连蛋白突变体及其表达菌株

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
AU2719088A (en) * 1987-11-09 1989-06-01 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0399666B1 (de) 1993-07-28
EP0407008A3 (en) 1991-07-17
DE69002395D1 (de) 1993-09-02
WO1990013306A3 (en) 1991-05-02
WO1990013306A2 (en) 1990-11-15
DK0399666T3 (da) 1993-08-30
DE69002395T2 (de) 1993-11-25
EP0399666A1 (de) 1990-11-28
ES2060033T3 (es) 1994-11-16
EP0407008A2 (de) 1991-01-09
GB8909919D0 (en) 1989-06-14

Similar Documents

Publication Publication Date Title
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
ZA943464B (en) Vascular endothelial growth factor 2
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ES2075155T3 (es) Separacion enzimatica de una secuencia de una proteina con amino terminal.
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
ATE150319T1 (de) Behandlung von asthma
RU93045577A (ru) Слитные полипептиды
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
NO923737D0 (no) Forbedret vevs-lim fremstilt ved anvendelse av kryopresipitat
ATE111484T1 (de) Verbindungen zur verhinderung von thrombose.
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
ES2078229T3 (es) Procedimiento para la preparacion de un polipeptido similar a la motilina y su expresion.
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time